Prothena outlines potential multi-billion dollar opportunity with birtamimab launch by 2026
Insights from Prothena's Q4 2024 call highlight 2025 milestones: pivotal trial results for birtamimab & Alzheimer's programs.
News Medical21h
Blood test for Alzheimer’s could replace costly and invasive spinal taps
Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...
Observer2d
Observer’s Guide to the L.A. Gallery and Museum Exhibitions to Check Out During Frieze
The MOCA Geffen is spotlighting two major crowd-pullers: Olafur Eliasson ’s seductive light installation OPEN, on view ...
WATCH: 'The DNA of TAU is about providing access for students to talk to people and ask questions'
Aharon, Ph.D., Co-Founder & CEO of AEYE Health, in conversation with Jake Laznik, Senior Breaking News Desk Manager, The ...
Medical News Today6d
New test may detect Alzheimer's years before tau clumps show up in scans
Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...